Over 7.5 million people will suffer from dementia from Alzheimer’s disease (AD) in the next decade, bringing a host of physical, emotional and legal challenges to those impacted by this degenerative illness and to their caregivers. Professor Betsy J. Grey makes a comprehensive and timely examination of questions that should be considered when it comes to the application of testing for biomarkers for AD in determining what she considers one of society’s most weighty decisions&mdash
All access premium subscription
Please Log in if you are currently a Trusts & Estates subscriber.
If you are interested in becoming a subscriber with unlimited article access, please select Subscription Options below.
Questions about your account or how to access content?
Contact: [email protected]
